AbbVie Inc.
ABBVDividend King • 52yrsAutomated dividend-safety read-out from payout, leverage, yield, profitability and track record. See the Financials tab for the full per-statement Financial Investigation. Educational only — not investment advice.
At a glance
AbbVie Inc. (ABBV) operates in the Drug Manufacturers - General industry and is based in the United States. It pays a quarterly dividend of $6.92 a year, a yield of 2.42% at the current price of $283.54. AbbVie has raised its dividend for 52 consecutive years, which makes it a Dividend King. Over the last five years the dividend has grown by an average of 6.8% a year. It paid out 117% of its earnings as dividends, more than it earned. 31 analysts cover it; their average 12-month price target of $315.88 is 11.4% above the current price.
Written automatically from the figures on this page, as of Nov 20, 2026. Facts only, not a recommendation.
About AbbVie Inc.
AbbVie Inc. , a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer.
Business description from Yahoo Finance. Verify details in the company's own annual report.
Key Metrics
Valuation
Profitability
Financial Health
Data provided by Yahoo Finance via yfinance. Updated daily. Not investment advice.